Halozyme Therapeutics Inc. (HALO)

Precedente Chiudi:

$39.30

Aprire:

$39.56

Volume 24 ore:

820.11K

Capitalizzazione di mercato:

$5.06B

Reddito:

$829.25M

Utile/perdita netta:

$281.59M

Rapporto P/E:

21.18

EPS:

1.88

Flusso di cassa netto:

$373.28M

1 W Prestazione:

+3.54%

1M Prestazione:

-1.51%

6M Prestazione:

+16.26%

1 anno Prestazione:

+25.14%

Intervallo 1D:

$38.88

$40.74

Portata 52W:

$29.85

$45.00

Halozyme Therapeutics Inc. Stock (HALO) Company Profile

Nome

Halozyme Therapeutics Inc.

Settore

Healthcare (1190)

Industria

Biotechnology (681)

Telefono

858-794-8889

Indirizzo

11388 Sorrento Valley Road, San Diego, CA

Dipendente

255

Cinguettio

@halozymeinc

Prossima data di guadagno

2024-05-07

Ultimi documenti SEC

HALO's Discussions on Twitter

Halozyme Therapeutics Inc. Stock (HALO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-07-24	Downgrade	Goldman	Buy → Neutral
2023-07-24	Iniziato	H.C. Wainwright	Buy
2023-05-10	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-03-27	Ripresa	Berenberg	Buy
2023-03-16	Downgrade	SVB Securities	Outperform → Market Perform
2022-12-21	Ripresa	Morgan Stanley	Overweight
2022-11-28	Iniziato	Wells Fargo	Overweight
2022-09-09	Iniziato	Morgan Stanley	Overweight
2022-05-23	Iniziato	SVB Leerink	Outperform
2021-06-14	Iniziato	Evercore ISI	Outperform
2021-05-17	Iniziato	SVB Leerink	Outperform
2021-05-11	Downgrade	Piper Sandler	Overweight → Neutral
2021-01-21	Reiterato	The Benchmark Company	Buy
2020-12-17	Iniziato	Berenberg	Buy
2020-09-14	Ripresa	JP Morgan	Overweight
2020-07-01	Iniziato	The Benchmark Company	Buy
2020-02-05	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-01-09	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2020-01-08	Iniziato	Goldman	Buy
2019-11-05	Aggiornamento	Barclays	Underweight → Equal Weight
2018-10-19	Ripresa	Piper Jaffray	Neutral
2018-05-11	Downgrade	Barclays	Equal Weight → Underweight
2018-01-24	Iniziato	Goldman	Neutral
2017-10-16	Reiterato	Piper Jaffray	Overweight
2017-01-06	Downgrade	Citigroup	Buy → Neutral
2016-11-03	Iniziato	Deutsche Bank	Buy
2015-12-04	Iniziato	Wells Fargo	Outperform
2015-11-18	Iniziato	Citigroup	Buy
2015-09-22	Iniziato	Barclays	Overweight
2015-06-22	Reiterato	JP Morgan	Overweight
2015-03-03	Reiterato	UBS	Buy
2015-02-18	Reiterato	MLV & Co	Buy
2015-01-08	Reiterato	MLV & Co	Buy

Mostra tutto

Halozyme Therapeutics Inc. Borsa (HALO) Ultime notizie

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

Zacks Investment Research

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Zacks Investment Research

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

Zacks Investment Research

Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research

9 Analysts Have This To Say About Halozyme Therapeutics

Benzinga

Halozyme Therapeutics Inc. Azioni (HALO) Dati Finanziari

Halozyme Therapeutics Inc. (HALO) Reddito 2024

Halozyme Therapeutics Inc. (HALO) Reddito netto 2024

Halozyme Therapeutics Inc. (HALO) Flusso di cassa 2024

Halozyme Therapeutics Inc. (HALO) Utile per azione 2024

Halozyme Therapeutics Inc. Azioni (HALO) insider trading